Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Indonesia ETF (EIDO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

iShares MSCI Indonesia ETFTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Indonesia ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.47, while Neurocrine Biosciences Inc trades at $159 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.

EIDONBIX
52-Week High
$19.22$185.50
52-Week Low
$10.80$123.10
Market Cap
$16.76B
Sector
Health
Enterprise Value
$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Indonesia ETF

EIDO, the iShares MSCI Indonesia ETF, trades at $12.91, up 2.38% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows support and resistance clustered around $13. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs and reforestation plans, while facing challenges from foreign capital outflows and central bank rate hikes to support the rupiah.

The outlook for EIDO is mixed, with low valuation offering potential upside, but weak price action and high financial sector exposure limit gains. Risks include geopolitical volatility and dependence on commodity markets, though government reforms could boost long-term growth. Investors should weigh bargain valuations against macroeconomic headwinds for balanced exposure.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Indonesia ETF

The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.

Read more on EIDO

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX